LONDON, UK, 24 March 2015 – Optos plc (LSE: OPTS), the leading medical retinal imaging company, today announces it has been awarded the prestigious 2014 Technology of The Year Award at the UK PLC Awards in London. 

The PLC Awards, now in its 29th year, is held annually to recognise success and achievement amongst publicly quoted companies in the UK.  Specifically, the Best Technology award is given to a company whose business growth and success is dependent on, or attributable to, the development of one or more technologies or on the development of technology-led products or services that require or have demonstrated significant innovation either in terms of the technology itself or its application.  Optos was nominated along with six other companies across all industry sectors including software, assurance and wireless technology. 

With more than 7,300 ultra-widefield (UWF™) retinal imaging devices installed worldwide, our customers support the principle that seeing more of the retina is important because it helps them manage and maintain their patient’s vision.  The latest UWF products, Daytona and California represent the newest generation of Optos ultra-widefield retinal imaging technology for the optometry and ophthalmology sectors.  Both devices are desktop models and provide high resolution and multiple imaging modalities.  The Company also manufactures optical coherence tomography (OCT) devices and optical ultrasound scanners, used in the diagnosis and management of eye disease and systemic conditions and is developing an integrated UWF and OCT device.    

Roy Davis, CEO of Optos, commented:  “We are delighted that Optos’s ultra-widefield retinal imaging has been recognised and honoured by this highly prestigious award.  We have been on a journey for the past few years, utilising the latest design and manufacturing technology and software to build new products with the objective of making optomap® images a standard of care.  In support of these new developments, we have also strengthened our clinical evidence to demonstrate the importance of imaging the entire retina and our commitment to helping eyecare professionals around the world save sight and lives.  This award is a reflection of the hard work of all of our employees to that end.  



Further details and images of the PLC award are available at

Information about Optos’ newest ultra-widefield retinal imaging devices can be found at


Optos plc
Roy Davis, CEO 
Robert Kennedy, CFO 

Tel: +44 (0) 1383 843 300

FTI Consulting
Ben Atwell / Mo Noonan / Simon Conway 

Tel: +44 (0) 20 3727 1000 


Note to Editors: Images available upon request


About Optos plc

Optos plc has the vision to be The Retina Company and recognised as a leading provider of devices to eyecare professionals for improved patient care. Optos' core devices produce ultra-widefield (UWF™), high resolution digital images (optomap®) of approximately 82% and 200 of the retina, something no other device is capable of doing in any single image.  An optomap image provides a bigger picture and more clinical information which facilitates the early detection, management and effective treatment of disorders and diseases evidenced in the retina such as retinal detachments and tears, glaucoma, diabetic retinopathy and age-related macular degeneration.  Retinal imaging can also indicate evidence of non-eye or systemic diseases such as hypertension and certain cancers.

Optos has a range of retinal imaging devices that support different customer segments and patient needs such as wellness screening carried out by optometrists in primary care settings or more exacting imaging in secondary care practices that are clinically managing a patient base with advanced ocular disease.  Our most advanced imaging devices for disease management and treatment support ophthalmologists and retinal specialists in the medical care market.

The latest products, Daytona and California represents the newest generation of Optos ultra-widefield retinal imaging technology and have been converted to desktop models while still providing high resolution images. For both devices, the ergonomic body is designed to increase patient comfort, as well as make it easier to correctly position the eye for image capture.  All image modalities; colour, red-free and autofluorescence (AF) are included in both devices.  California features fluorescein angiography (FA) and our newest UWF imaging modality, indocyanine green angiography (ICG).  ICG is used for imaging the choroidal vasculature which is important for the diagnosis, management and treatment of certain conditions such as neovascular age-related macular degeneration (AMD) and disorders with choroidal neovascular membranes. 

Optos also offers optical coherence tomography (OCT) devices and optical ultrasound scanners, used in the diagnosis and management of eye disease and systemic conditions.  OCT delivers an image that shows a three dimensional, cross-sectional view of the retina in the central area of the retina around the optic nerve and macula and is used to detect the presence of and understand the severity of disease, determine treatment approaches and monitor post-treatment effect.  Currently under product development is an ultra-widefield retinal imaging device combined with OCT.  This united device has the potential to offer ophthalmologists and optometrists the most powerful tools for disease diagnosis, monitoring and management.  Beyond ultra-widefield imaging and OCT, the company’s expanded product range now includes visual acuity, perimetry and treatment laser products.

Optos is committed to utilising the latest technology to manufacture new products and software that support optomap as a standard of care therefore helping eyecare professionals around the world save sight and lives.  Furthermore the company continues to strengthen its clinical evidence and expand its disease indications to demonstrate the importance of imaging the entire retina.

Forward-Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates and projections about its industry, its beliefs and assumptions.  Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the Company's control, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.